1
|
Dimarakis I, Callan P, Khorsandi M, Pal JD, Bravo CA, Mahr C, Keenan JE. Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices. Front Cardiovasc Med 2022; 9:1029825. [PMID: 36407458 PMCID: PMC9669306 DOI: 10.3389/fcvm.2022.1029825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2022] [Accepted: 09/29/2022] [Indexed: 11/06/2022] Open
Abstract
Over the last two decades, implantable continuous flow left ventricular assist devices (LVAD) have proven to be invaluable tools for the management of selected advanced heart failure patients, improving patient longevity and quality of life. The presence of concomitant valvular pathology, including that involving the tricuspid, mitral, and aortic valve, has important implications relating to the decision to move forward with LVAD implantation. Furthermore, the presence of concomitant valvular pathology often influences the surgical strategy for LVAD implantation. Concomitant valve repair or replacement is not uncommonly required in such circumstances, which increases surgical complexity and has demonstrated prognostic implications both short and longer term following LVAD implantation. Beyond the index operation, it is also well established that certain valvular pathologies may develop or worsen over time following LVAD support. The presence of pre-existing valvular pathology or that which develops following LVAD implant is of particular importance to the destination therapy LVAD patient population. As these patients are not expected to have the opportunity for heart transplantation in the future, optimization of LVAD support including ameliorating valvular disease is critical for the maximization of patient longevity and quality of life. As collective experience has grown over time, the ability of clinicians to effectively address concomitant valvular pathology in LVAD patients has improved in the pre-implant, implant, and post-implant phase, through both medical management and procedural optimization. Nevertheless, there remains uncertainty over many facets of concomitant valvular pathology in advanced heart failure patients, and the understanding of how to best approach these conditions in the LVAD patient population continues to evolve. Herein, we present a comprehensive review of the current state of the field relating to the pathophysiology and management of valvular disease in destination LVAD patients.
Collapse
Affiliation(s)
- Ioannis Dimarakis
- Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States
- Department of Cardiothoracic Transplantation, Manchester University Hospital NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom
| | - Paul Callan
- Department of Cardiothoracic Transplantation, Manchester University Hospital NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom
| | - Maziar Khorsandi
- Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States
| | - Jay D. Pal
- Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States
| | - Claudio A. Bravo
- Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States
| | - Claudius Mahr
- Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States
| | - Jeffrey E. Keenan
- Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States
| |
Collapse
|
2
|
Gautier SV, Itkin GP, Shevchenko AO, Khalilulin TA, Kozlov VA. DURABLE MECHANICAL CIRCULATION SUPPORT AS AN ALTERNATIVE TO HEART TRANSPLANTATION. ACTA ACUST UNITED AC 2016. [DOI: 10.15825/1995-1191-2016-3-128-136] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
In the review a comparative analysis of the treatment of end-stage chronic heart failure using heart transplantation and durable mechanical circulatory is conducted. It shows the main advantages and limitations of heart transplantation and the prospects of application of durable mechanical circulatory support technology. The main directions of this technology, including two-stage heart transplant (bridge to transplant – BTT), assisted circulation for myocardial recovery (bridge to recovery – BTR) and implantation of an auxiliary pump on a regular basis (destination therapy, DT).
Collapse
Affiliation(s)
- S. V. Gautier
- V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow
| | - G. P. Itkin
- V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow; Moscow Institute of Physics and Technology (State University), Department of physics of living systems, Moscow
| | - A. O. Shevchenko
- V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow; N.I. Pirogov First Moscow State Medical University, Moscow
| | - T. A. Khalilulin
- V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow; N.I. Pirogov First Moscow State Medical University, Moscow
| | - V. A. Kozlov
- Moscow Institute of Physics and Technology (State University), Department of physics of living systems, Moscow
| |
Collapse
|
3
|
Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare. Surg Today 2014; 45:672-81. [DOI: 10.1007/s00595-014-0957-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2014] [Accepted: 05/12/2014] [Indexed: 10/24/2022]
|
4
|
Chu SK, McCormick Z, Hwang S, Sliwa JA, Rydberg L. Outcomes of Acute Inpatient Rehabilitation of Patients With Left Ventricular Assist Devices. PM R 2014; 6:1008-12. [DOI: 10.1016/j.pmrj.2014.05.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Revised: 04/03/2014] [Accepted: 05/03/2014] [Indexed: 01/31/2023]
|
5
|
Choi SW, Park SM. Analysis of Left Ventricular Impedance in Comparison With Ultrasound Images. Artif Organs 2011; 36:479-86. [DOI: 10.1111/j.1525-1594.2011.01381.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Nissinoff J, Tian F, Therattil M, Salvarrey RM, Lee SW. Acute Inpatient Rehabilitation After Left Ventricular Assist Device Implantation for Congestive Heart Failure. PM R 2011; 3:586-9. [DOI: 10.1016/j.pmrj.2010.11.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2010] [Revised: 11/16/2010] [Accepted: 11/19/2010] [Indexed: 10/18/2022]
|
7
|
Schulman AR, Martens TP, Russo MJ, Christos PJ, Gordon RJ, Lowy FD, Oz MC, Naka Y. Effect of Left Ventricular Assist Device Infection on Post-transplant Outcomes. J Heart Lung Transplant 2009; 28:237-42. [DOI: 10.1016/j.healun.2008.12.007] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2008] [Revised: 09/24/2008] [Accepted: 12/01/2008] [Indexed: 10/21/2022] Open
|
8
|
Right Heart Dysfunction After Left Ventricular Assist Device Implantation: A Comparison of the Pulsatile HeartMate I and Axial-Flow HeartMate II Devices. Ann Thorac Surg 2008; 86:832-40; discussion 832-40. [DOI: 10.1016/j.athoracsur.2008.05.016] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Revised: 04/30/2008] [Accepted: 05/05/2008] [Indexed: 11/23/2022]
|
9
|
Long JW, Healy AH, Rasmusson BY, Cowley CG, Nelson KE, Kfoury AG, Clayson SE, Reid BB, Moore SA, Blank DU, Renlund DG. Improving outcomes with long-term “destination” therapy using left ventricular assist devices. J Thorac Cardiovasc Surg 2008; 135:1353-60; discussion 1360-1. [DOI: 10.1016/j.jtcvs.2006.09.124] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2006] [Revised: 08/16/2006] [Accepted: 09/05/2006] [Indexed: 11/25/2022]
|
10
|
Choi JH, Jun ES. Treatment of Medically Intractable End-Stage Heart Failure. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION 2008. [DOI: 10.5124/jkma.2008.51.4.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Affiliation(s)
- Jin-Ho Choi
- Department of Emergency Medicine, Sungkyunkwan University School of Medicine, Korea.
| | - Eun Seok Jun
- Department of Cardiology, Sungkyunkwan University School of Medicine, Korea.
| |
Collapse
|
11
|
|
12
|
Zierer A, Melby SJ, Voeller RK, Guthrie TJ, Ewald GA, Shelton K, Pasque MK, Moon MR, Damiano RJ, Moazami N. Late-Onset Driveline Infections: The Achilles’ Heel of Prolonged Left Ventricular Assist Device Support. Ann Thorac Surg 2007; 84:515-20. [PMID: 17643627 DOI: 10.1016/j.athoracsur.2007.03.085] [Citation(s) in RCA: 133] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2007] [Revised: 03/24/2007] [Accepted: 03/27/2007] [Indexed: 10/23/2022]
Abstract
BACKGROUND A successful left ventricular assist device (LVAD) long-term support in an outpatient setting demands that device-related complications are reduced to a minimum. We hypothesized that late onset driveline infections have serious implications on the anticipated application of LVAD as permanent therapy. METHODS Between 1996 and 2005, 73 patients were implanted with the Novacor (World Heart Corp, Ottawa, Ontario, Canada; n = 35) or the HeartMate (Thoratec Corp, Pleasanton, CA; n = 38) as either bridge to transplantation (n = 44) or destination therapy (n = 29). Our analysis focused on patients with late-onset infection (> or = 30 days) of the driveline exit site with prior clinical healing of all incisions. RESULTS Late driveline infections developed in 17 patients (23%) at a median of 158 days (intraquartile range [IQR]: 68 to 213 days) after implantation. The median duration of support in this subgroup was 400 days (IQR, 283 to 849 days). Despite an aggressive treatment algorithm, repeat surgical revision was needed in 12 patients, up to six times in 2 individuals. In 6 patients, the infection progressed to pump pocket infections that led to urgent heart transplantation (n = 4) or explantation (n = 2). The individual risk that a driveline infection would develop dramatically increased with the duration of support, reaching 94% at 1 year. Multivariate analysis identified duration of support (p < 0.001) and documented trauma at the driveline exit site (p < 0.001) as independent predictors of infection. Number and duration of readmissions to the hospital significantly increased (p < 0.001), and long-term follow-up for survival (4.4 +/- 2.2 years, 100% complete) showed a trend towards impaired outcome after driveline infection (5-year survival: 41% versus 70%, p = 0.10). CONCLUSIONS Long-term LVAD support in the current series was jeopardized by late-onset driveline infections, which occurred in all patients with support duration longer than 1 year. Once driveline infections developed, they were difficult to control and significantly increased morbidity.
Collapse
Affiliation(s)
- Andreas Zierer
- Division of Cardiothoracic Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Missouri 62236, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Sapirstein W, Chen E, Swain J, Zuckerman B. US FDA perspective on regulatory issues affecting circulatory assist devices. Expert Rev Med Devices 2007; 3:749-53. [PMID: 17280539 DOI: 10.1586/17434440.3.6.749] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
There has been a rapid development in mechanical circulatory support systems in the decade since the US FDA first approved a mechanical device to provide the circulatory support lacking from a failing heart. Devices are presently approved for marketing by the FDA to replace a failing ventricle, the Ventricular Assist Device or the entire heart, Total Artificial Heart. Contemporaneous with, and permitted by, improvement in technology and design, devices have evolved from units located extracorporeally to paracorporeal systems and totally implanted devices. Clinical studies have demonstrated a parallel improvement in the homeostatic adequacy of the circulatory support provided. Thus, while the circulatory support was initially tolerated for short periods to permit recovery of cardiac function, this technology eventually provided effective circulatory support for increasing periods that permitted the FDA to approve devices for bridging patients in end-stage cardiac failure awaiting transplant and eventually a device for destination therapy where patients in end-stage heart failure are not cardiac transplant candidates. The approved devices have relied on displacement pumps that mimic the pulsatility of the physiological system. Accelerated development of more compact devices that rely on alternative pump mechanisms have challenged both the FDA and device manufacturers to assure that the regulatory requirements for safety and effectiveness are met for use of mechanical circulatory support systems in expanded target populations. An FDA regulatory perspective is reviewed of what can be a potentially critical healthcare issue.
Collapse
Affiliation(s)
- Wolf Sapirstein
- Division of Cardiovascular Devices, Office of Device Evaluation, Center for Devices and Radiological Health, US FDA, Rockville, MD 20850, USA.
| | | | | | | |
Collapse
|
14
|
Pae WE, Connell JM, Boehmer JP, Korfer R, El-Banayosy A, Hetzer R, Vigano M, Pavie A. Neurologic Events With a Totally Implantable Left Ventricular Assist Device: European LionHeart Clinical Utility Baseline Study (CUBS). J Heart Lung Transplant 2007; 26:1-8. [PMID: 17234510 DOI: 10.1016/j.healun.2006.10.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2006] [Revised: 09/15/2006] [Accepted: 10/19/2006] [Indexed: 10/23/2022] Open
Abstract
BACKGROUND Neurologic events such as thromboembolic and hemorrhagic strokes are common complications of mechanical circulatory support. We report the neurologic events observed in patients treated for end-stage heart failure with the implantable, pulsatile LionHeart left ventricular assist device (LVAD). This sub-study was part of the LionHeart European Clinical Utility Baseline Study (CUBS). METHODS Twenty-three male patients were implanted with the LionHeart LVAD in a non-randomized, observational study. Neurologic events were classified into three categories: (1) transient ischemic attacks (TIAs); (2) strokes, including cerebrovascular accidents (CVAs) and intracranial bleeding (ICB); and (3) "other," including hypoperfusion, coma and brain death. Neurologic injuries were also categorized as transient/reversible or permanent/disabling. RESULTS Thirteen of 23 patients (57%) had a total of 30 neurologic events. Eight patients (35%) had 18 TIAs. Eight patients (35%) also had a stroke, either CVA (n = 5, 22%) or ICB (n = 3, 13%), and 5 of these patients (22%) also had 12 TIAs. Three patients (13%) had 4 "other" neurologic events. Ten patients (43%) had transient/reversible neurologic deficits and 10 (43%) had permanent/disabling events. One patient (4%) had intracranial bleeding as a primary cause of death (anti-coagulation-related hemorrhage). The combined incidence of neurologic events was 1.37 events/patient-year. The incidences of transient and permanent events were 0.91 and 0.46 event/patient-year, respectively. CONCLUSIONS Neurologic events caused morbidity in the CUBS trial, with infrequent mortality. These results are similar to previous experiences with destination therapy and underscore the need for improvements in LVAD design, patient selection and patient management to reduce the incidence of neurologic events.
Collapse
Affiliation(s)
- Walter E Pae
- Heart and Vascular Institute, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033-0850, USA.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Sajjadian A, Valerio IL, Acurturk O, Askari MA, Sacks J, Kormos RL, Manders EK. Omental Transposition Flap for Salvage of Ventricular Assist Devices. Plast Reconstr Surg 2006; 118:919-926. [PMID: 16980851 DOI: 10.1097/01.prs.0000232419.74219.15] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND The use of ventricular assist devices for patients with end-stage cardiac failure awaiting heart transplantation has become increasingly common. Ventricular assist devices improve the longevity and the quality of life for these patients. In addition, they serve as a bridge to cardiac allograft transplantation until a donor heart is found. However, ventricular assist device-related infections remain a major problem complicating their long-term use. Clinical infection and sepsis can critically threaten these patients with ventricular assist devices. Infection can delay immediate transplantation and potentially require the removal of the device for definitive treatment of the problem. METHODS Patients who underwent insertion of a ventricular assist device at the University of Pittsburgh Medical Center were identified through accessing the medical records archives of the hospital. Review of patients' medical records was conducted to obtain patient demographics, preoperative diagnosis and disease state, type of ventricular assist device inserted, postoperative day of ventricular assist device infection onset, infectious organism identified, timing of omental flap procedure after the initial insertion, duration of ventricular assist device support before cardiac transplantation, and patient follow-up. RESULTS There were 76 patients who underwent a ventricular assist device insertion procedure during the 4-year period between January of 2000 and January of 2004. Of the 76 patients who received a device, 11 (14 percent) had evidence of clinical infection secondary to insertion. Two of these 11 patients died before surgical intervention, four had their devices explanted, and the remaining five underwent omental flap transposition with bilateral pectoralis major advancement flaps in surgically addressing their infections. Of the five patients with infections who received omental transposition flaps, two went on to undergo successful transplantation, two continue to await cardiac allograft transplantation, and one died as a result of an unknown cause. CONCLUSIONS The authors present their experience with five patients who received omental transposition flaps to cover infected ventricular assist device pumps and the associated tubing in large, open sternoabdominal wounds. Treatment included the direct application of an omental transposition flap over the infected device with use of a bilateral pectoralis advancement flap to aid in complete sternal and skin closure of the sternal wound defect. In each of these cases, the use of the omental flap was followed by resolution of the mediastinal infection. In addition, the treatment with an omental flap prevented the removal of infected devices in patients who were otherwise pump dependent during their waiting periods for transplantation. The use of omental transposition flaps can be an effective technique in salvaging infected ventricular assist devices and preserving this valuable device for patients awaiting a cardiac transplant.
Collapse
Affiliation(s)
- Ali Sajjadian
- Pittsburgh, Pa. From the Division of Plastic and Reconstructive Surgery, University of Pittsburgh Medical Center
| | | | | | | | | | | | | |
Collapse
|
16
|
Digiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant 2006; 24:200-4. [PMID: 15701438 DOI: 10.1016/j.healun.2003.11.397] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2003] [Revised: 11/03/2003] [Accepted: 11/03/2003] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND With the increasing clinical success of left ventricular assist devices (LVADs), physicians need to measure device cost efficacy to determine the societal value of this technology. Today's large clinical volume allows comparison of the costs of this innovation as compared with orthotopic heart transplant (OHT). METHODS We evaluated hospital cost and reimbursement for patients who were discharged after LVAD implantation and returned to the hospital for OHT. To control for patient-specific variables, LVAD therapy and OHT therapy were compared in the same patient; that is, only those patients who received an LVAD were discharged, and returned for OHT were studied. Length of stay (LOS), re-admissions and outpatient services were analyzed, including their respective total actual hospital cost (TAHC) and net revenue (NR). Time periods analyzed were the same for LVAD and OHT. RESULTS From the LVAD population at Columbia-Presbyterian Medical Center, 36 patients were discharged following HeartMate vented electric (VE) implantation and re-admitted for OHT between December 1996 and June 2000. Mean pre-LVAD implantation LOS was 21.3 +/- 24.1 days. Post-LVAD LOS was 36.8 +/- 22.2 days vs 18.2 +/- 12.2 days post-OHT (p < 0.001). Mean length of LVAD support was 123.4 +/- 77.7 days. Overall total costs for LVADs exceeded that of OHT, whereas revenue was relatively lower. TAHC post-LVAD averaged $197,957 +/- 77,291, whereas TAHC post-OHT averaged $151,646 +/-53,909 (p = 0.005). NR averaged $144,756 +/- 96,656 post-LVAD vs $178,562 +/- 68,571 post-OHT (p = 0.09). LVAD patients had more re-admissions compared with OHT: 1.2/123 days (+/- 1.7) vs 0.3/123 days (+/- 0.6), respectively (p = 0.005). The average LOS during a re-admission was similar between the 2 groups (LVAD 5.6 days [+/- 10.6] vs OHT 9.6 days [+/- 8.2]; p = 0.18). OHT was associated with a significantly greater number of outpatient services compared with LVAD (9.7 [+/- 6.1] vs 3.0 [+/- 4.7]; p < 0.001). In contrast to OHT, revenues did not match the costs of LVAD therapy. CONCLUSIONS LVAD implantation is associated with longer LOS and higher cost for initial hospitalization compared with OHT. LVAD patients have higher re-admission rates compared with OHT but similar costs and LOS. OHT is associated with a greater number of outpatient services. Reimbursements for LVAD therapy are relatively low, resulting in significant lost revenue. If LVAD therapy is to become a viable alternative, improvements in both cost-effectiveness and reimbursement will be necessary.
Collapse
Affiliation(s)
- Paul L Digiorgi
- Department of Surgery, Division of Cardiothoracic Surgery, Columbia University, New York, NY 10032, USA.
| | | | | | | | | | | |
Collapse
|
17
|
Petrucci RJ, Truesdell KC, Carter A, Goldstein NE, Russell MM, Dilkes D, Fitzpatrick JM, Thomas CE, Keenan ME, Lazarus LA, Chiaravalloti ND, Trunzo JJ, Verjans JW, Holmes EC, Samuels LE, Narula J. Cognitive Dysfunction in Advanced Heart Failure and Prospective Cardiac Assist Device Patients. Ann Thorac Surg 2006; 81:1738-44. [PMID: 16631665 DOI: 10.1016/j.athoracsur.2005.12.010] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2005] [Revised: 12/01/2005] [Accepted: 12/02/2005] [Indexed: 11/26/2022]
Abstract
BACKGROUND Extended periods of hypoperfusion in an advanced heart failure (HF) places patients at high risk for neurobehavioral compromise, which has not been studied systematically. It is also not clear how intravenous inotropic therapy and mechanical cardiac assist devices (MCAD) affect cognitive function. METHODS This prospective cross-sectional cognitive preliminary study evaluated 252 potential heart transplant candidates assessing functions in memory, motor, and processing speed. Patients were divided into three HF groups based on severity of disease: group 1 outpatients (n = 113), group 2 in-patients requiring inotropic infusion (n = 83), and group 3 inpatients likely requiring MCAD support (n = 56). Aggregate z-scores for memory, motor, and processing speed and independent samples t tests assessed intergroup differences on 13 cognitive measures. RESULTS A broad pattern of cognitive impairment was observed within the advanced HF group; fewer deficits were found in group 1 outpatients and more severe deficits in group 3 MCAD subjects. A difference in motor functions was observed as the earliest abnormality, with group 3 showing significant changes compared with group 1. The most dramatic changes were seen in domain mental processing speed along with specific verbal and visual memory functions, which were slower in group 3 compared with groups 1 and 2. CONCLUSIONS Cognitive deficits are common in advanced HF and worsen with increasing severity of HF. Appropriately designed and randomized studies will be needed to demonstrate if earlier MCAD implantation is warranted to arrest cognitive dysfunction and better postimplantation adaptation.
Collapse
Affiliation(s)
- Ralph J Petrucci
- College of Medicine, Drexel University, Philadelphia, Pennsylvania 19102, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Thoennissen NH, Schneider M, Allroggen A, Ritter M, Dittrich R, Schmid C, Scheld HH, Ringelstein EB, Nabavi DG. High level of cerebral microembolization in patients supported with the DeBakey left ventricular assist device. J Thorac Cardiovasc Surg 2005; 130:1159-66. [PMID: 16214534 DOI: 10.1016/j.jtcvs.2005.02.068] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2004] [Revised: 02/16/2005] [Accepted: 02/22/2005] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Microembolic signals detected by transcranial Doppler ultrasonography have been demonstrated to be clinically relevant in patients supported with pulsatile left ventricular assist devices. We prospectively investigated the quantity of microembolic signals in patients supported with the continuous-flow DeBakey left ventricular assist device (MicroMed DeBakey VAD; MicroMed Technology, Inc, Houston, Tex) including the refined Carmeda BioActive Surface system (Carmeda AB, Stockholm, Sweden). METHODS Twenty-three patients (20 male) aged 14 to 62 years supported with DeBakey left ventricular assist devices (n = 6 with Carmeda) were enrolled in this study. Microembolic signal monitorings were performed twice weekly by insonating the middle cerebral artery for 20 minutes without and 20 minutes with oronasal application of oxygen (6 L/min). Evidence of clinically manifest thromboembolic events was based on regular questionnaires, clinical examinations, and results of diagnostic procedures. RESULTS Despite a low incidence of thromboembolic complications (0.24 per 100 left ventricular assist device days), 20 patients (87%) showed circulating microemboli. Overall, microembolic signals were found in 175 of 499 transcranial Doppler ultrasonographic examinations (35.1%), with mean counts of 81.2 +/- 443 (range 0-5042 signals/h). Both microembolic signal prevalence (25% vs 34%, P = .01) and absolute signal counts (46.5 vs 104, P < .01) significantly declined with oxygen delivery. There was no significant correlation between the individual microembolic signal activity and the incidence of clinical thromboembolism or the intensity of antihemostatic treatment. Patients supported with the Carmeda device did not show reduced rates of clinical thromboembolization or cerebral microemboli. CONCLUSION In patients with DeBakey left ventricular assist devices, a high load of clinically silent microemboli can be detected within the cerebral arteries despite a low incidence of embolic complications. It needs to be investigated whether such continuous, presumably gaseous microembolization causes cognitive or neuropsychologic deficits.
Collapse
|
19
|
Park SJ, Tector A, Piccioni W, Raines E, Gelijns A, Moskowitz A, Rose E, Holman W, Furukawa S, Frazier OH, Dembitsky W. Left ventricular assist devices as destination therapy: A new look at survival. J Thorac Cardiovasc Surg 2005; 129:9-17. [PMID: 15632819 DOI: 10.1016/j.jtcvs.2004.04.044] [Citation(s) in RCA: 166] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE The REMATCH trial compared the use of left ventricular assist devices with optimal medical management for patients with end-stage heart failure. When the trial met its primary end point criteria in July 2001, left ventricular assist device therapy was shown to significantly improve survival and quality of life. With extended follow-up, 2 critical questions emerge: (1) Did these benefits persist, and (2) did outcomes improve over the course of the trial, given the evolving nature of the technology? METHODS We analyzed survival in this randomized trial by using the product-limit method of Kaplan and Meier. Changes in the benefits of therapy were analyzed by examining the effect of the enrollment period. RESULTS The survival rates for patients receiving left ventricular assist devices (n = 68) versus patients receiving optimal medical management (n = 61) were 52% versus 28% at 1 year and 29% versus 13% at 2 years ( P = .008, log-rank test). As of July 2003, 11 patients were alive on left ventricular assist device support out of a total 16 survivors (including 3 patients receiving optimal medical management who crossed over to left ventricular assist device therapy). There was a significant improvement in survival for left ventricular assist device-supported patients who enrolled during the second half of the trial compared with the first half ( P = .03). The Minnesota Living with Heart Failure scores improved significantly over the course of the trial. CONCLUSION The extended follow-up confirms the initial observation that left ventricular assist device therapy renders significant survival and quality-of-life benefits compared with optimal medical management for patients with end-stage heart failure. Furthermore, we observed an improvement in the survival of patients receiving left ventricular assist devices over the course of the trial, suggesting the effect of greater clinical experience.
Collapse
|
20
|
Goldstein DJ. Worldwide experience with the MicroMed DeBakey Ventricular Assist Device as a bridge to transplantation. Circulation 2003; 108 Suppl 1:II272-7. [PMID: 12970245 DOI: 10.1161/01.cir.0000087387.02218.7e] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Ventricular assist device (VAD) support with pulsatile first generation pumps is a well-established therapy for bridging to transplantation. Shortcomings of this technology include limited applicability to small patients, noise, and high incidence of infection and pump malfunction. A second generation of pumps, spearheaded by the axial flow MicroMed DeBakey VAD, is in clinical trials and potentially will address these shortcomings. METHODS AND RESULTS Between November 13, 1998 and May 7, 2002, 150 patients worldwide underwent placement of the Micromed DeBakey VAD as a bridge to transplantation. Prospectively acquired data including demographics, adverse events and outcomes was collected. Follow up is 100% with 30.4 patient-years of cumulative support time. Mean age was 48+/-4 years and 18% were female. Twenty-three percent had prior sternotomy. Preoperatively, 25% were on balloon pump support, 20% had renal insufficiency, and 40% were on at least two inotropes with a mean cardiac index of 1.8 L/min/m2. Mean support time was 75+/-81 days. Linearized rates (events/patient-year) were: reoperation for bleeding 2.03, hemolysis 0.61, device infection 0.16, thromboembolic event 0.61, pump thrombus 0.61, and pump failure 0.13. Eight-two patients (55%) were either bridged to transplantation, recovery or are ongoing and 68 (45%) have died. Several patients have been supported as outpatients. CONCLUSIONS This initial experience suggests that bridging to transplantation can be successfully approached with a small and quiet axial flow pump that provides low incidence of device infection and pump failure. The incidence of pump thrombus and thromboembolism is being addressed by incorporation of heparin coating to all device surfaces.
Collapse
Affiliation(s)
- Daniel J Goldstein
- Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, 201 Lyons Avenue, Suite G5, Newark, NJ 07112, USA.
| |
Collapse
|
21
|
Poston RS, Husain S, Sorce D, Stanford E, Kusne S, Wagener M, Griffith BP, Kormos RL. LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. J Heart Lung Transplant 2003; 22:914-21. [PMID: 12909473 DOI: 10.1016/s1053-2498(02)00645-9] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
INTRODUCTION Patients who have ventricular assist devices (VADs) and experience bloodstream infection (BSI) have high mortality. We addressed 2 questions raised by the United Network for Organ Sharing (UNOS) priority policy for this problem: 1) Are organs wasted on this ultra-high-risk group? 2) Can device-related BSI be differentiated from transient BSI? METHODS Patients with VADs who underwent heart transplantation from 1987 to 2001, who had BSI during VAD support, and who had positive cultures at VAD explant (device-related BSI, n = 10) were compared with those with negative cultures at explant (non-device-related BSI, n = 11). RESULTS Patients with device-related BSI had an 80% (8/10) rate of persistent bacteremia; 30 days and 1 year after transplantation, mortality was 14% and 26%, respectively. Non-device-related BSI (n = 11) persisted in 18% (2/11); peri-operative and 1-year mortalities were 9% and 13%. Duration of VAD support predicted infection (132 vs 48 days, p < 0.001); hypo-albuminemia (2.9 +/- 0.5 mg/dl vs 3.3 +/- 0.8 mg/dl, p < 0.05), and a resistant organism predicted a device-related BSI. These patients had increased intubation requirements and had increased creatinine concentration during the first post-operative week, with no difference in liver function, blood loss, transfusions (packed red blood cells, fresh frozen plasma, or platelets), or hemodynamic stability vs patients with non-device BSI. Despite decreased immunosuppression, we found no difference in acute rejection events with device-related BSI. Re-infection with the pre-operative organism occurred in only 1 patient per group. CONCLUSIONS These data suggest that urgent (Status 1A) cardiac transplantation is effective in stable patients with device-related BSI, and these data support the current UNOS policy. However, an extra-device source of BSI should be excluded by considering the isolated organism, the baseline nutritional status, and other risk factors.
Collapse
Affiliation(s)
- Robert S Poston
- Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Nabavi DG, Stockmann J, Schmid C, Schneider M, Hammel D, Scheld HH, Ringelstein EB. Doppler microembolic load predicts risk of thromboembolic complications in Novacor patients. J Thorac Cardiovasc Surg 2003; 126:160-7. [PMID: 12878951 DOI: 10.1016/s0022-5223(03)00019-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Left ventricular assist devices have become an established method to bridge patients with end-stage cardiac failure to heart transplantation. Besides infection and bleeding, thromboembolism represents one of the most serious complications. We evaluated the value of microembolic signals in predicting thromboembolic events for individual patients and distinctive left ventricular assist device periods. METHODS Twenty patients (14 male) aged 23-57 years supported with the Novacor N100 left ventricular assist device were enrolled in this study. All patients were on effective anticoagulation, 12 patients additionally received antiplatelet therapy. Unilateral detection of microembolic signals was performed once weekly by insonation of the middle cerebral artery using transcranial Doppler sonography for 30 minutes duration. Evidence of clinically manifest thromboembolic events was based on regular questionnaires, clinical examinations, and results of diagnostic procedures. RESULTS During a cumulative follow-up of 3876 left ventricular assist device days, 44 thromboembolic complications occurred (incidence, 1.1%) in 15 out of 20 patients. A total of 360 transcranial Doppler sonography monitorings (range, 5-34 per patient) were performed with an overall microembolic signals prevalence of 35.3% and a microembolic signal mean of 2.3 +/- 9.2 per examination. There was a highly significant correlation between the individual microembolic signal activity and the respective incidence of clinical thromboembolism (r = 0.61-0.9; P <.01). Patients with additional antiplatelet treatment had significantly less thromboembolic complications (0.7%) and lower microembolic signal prevalence (18.3%) than those without (2.8% and 65.4%, respectively). Individual patients and left ventricular assist device months with clinical thromboembolization could be identified using the microembolic signal activity with moderate positive (0.37-0.7) and high negative predictive values (0.82-1.0). CONCLUSIONS The amount of microembolic signals, serially detected in patients with the Novacor left ventricular assist device, is significantly associated with their incidence of embolic complications. The high negative predictive value of microembolic signals enables to identify those patients and left ventricular assist device periods with particularly low risk of clinical thromboembolization.
Collapse
|
23
|
Abstract
Of the 400,000 people in the United States who develop end-stage heart failure each year, 60,000 are unresponsive to medical therapy and 2,500 undergo heart transplantation. Surgically implanted pumps, called LVADs, are extending many lives.
Collapse
Affiliation(s)
- A Elaine Bond
- College of Nursing, Brigham Young University, Provo, UT, USA.
| | | | | | | |
Collapse
|
24
|
Bramstedt KA, Simeon DJ. The challenges of responding to "high-tech" cardiac implant patients in crisis. PREHOSP EMERG CARE 2002; 6:425-32. [PMID: 12385611 DOI: 10.1080/10903120290938076] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Complex new technologies are frequently added to the palate of modern cardiac care, and numerous potential technologies are poised for patient availability upon successful clinical trials. Some cardiac implants, while thoroughly understood by many cardiologists and most cardiac surgeons, are poorly understood by prehospital (e.g., paramedic, emergency medical technician) and emergency department care providers (e.g., physicians, nurses, respiratory therapists), potentially facilitating improper or inadequate patient care. Exploring the technologies of coronary stents, left ventricular assist devices, and the currently experimental total artificial heart, it is offered that prehospital and emergency department care providers (and ultimately their patients) would benefit by formal training regarding these devices.
Collapse
Affiliation(s)
- Katrina A Bramstedt
- Department of Community Medicine and General Practice, Monash University, East Bentleigh, Victoria, Australia.
| | | |
Collapse
|
25
|
Grady KL, Meyer P, Mattea A, Dressler D, Ormaza S, White-Williams C, Chillcott S, Kaan A, Todd B, Loo A, Klemme AL, Piccione W, Costanzo MR. Predictors of Quality of Life at 1 Month After Implantation of a Left Ventricular Assist Device. Am J Crit Care 2002. [DOI: 10.4037/ajcc2002.11.4.345] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
• Objectives To describe quality-of-life outcomes; determine relationships between quality of life and demographic, physical, psychosocial, and clinical variables; and identify predictors of quality of life at 1 month after implantation of a left ventricular assist device.
• Methods Patients who received either an implantable pneumatic (n = 38) or a vented electric (n = 54) left ventricular assist device as a bridge to heart transplantation between August 1, 1994, and August 31, 1999, completed 6 instruments used to measure quality of life and factors related to quality of life. Data were analyzed by using descriptive statistics, Pearson correlations, Mann-Whitney U tests, and forward, stepwise multiple regression.
• Results Overall satisfaction with quality of life was quite high as determined from the total score on the Quality of Life Index (mean = 0.69). Patients were very satisfied with the implantation and thought that they would do well after future heart transplant surgery. Patients had a moderate level of stress. Significant predictors of overall quality of life were psychological symptoms, stress, and race; these accounted for 46% of variance in quality of life.
• Conclusions Patients were satisfied with their quality of life at 1 month after implantation of a left ventricular assist device. However, they were least satisfied with their health and functioning and yet were optimistic about how well they thought they would do after heart transplantation. Psychological factors were the strongest predictors of satisfaction with overall quality of life.
Collapse
Affiliation(s)
- Kathleen L. Grady
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Peter Meyer
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Annette Mattea
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Diane Dressler
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Sophia Ormaza
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Connie White-Williams
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Suzanne Chillcott
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Annemarie Kaan
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Barbara Todd
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Alice Loo
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Annette L. Klemme
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - William Piccione
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| | - Maria Rosa Costanzo
- Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Ill (KLG, PM, AM, WP, MRC), St. Luke’s Medical Center, Milwaukee, Wis (DD), University of Minnesota, Minneapolis, Minn (SO), University of Alabama, Birmingham, Ala (CW-W), Sharp Memorial Hospital, San Diego, Calif (SC), St. Vincent’s Hospital, Darlinghurst, Australia (AK), Temple University, Philadelphia, Pa (BT), University of Pennsylvania, Philadelphia, Pa (AL), and Fairfax Hospital, Falls Church, Va (ALK)
| |
Collapse
|
26
|
McCafferty M, Sorbellini D, Cianci P. Telemetry to Home: Successful Discharge of Patients With Ventricular Assist Devices. Crit Care Nurse 2002. [DOI: 10.4037/ccn2002.22.3.43] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- Maureen McCafferty
- Maureen McCafferty is an advanced practice nurse with MidAmerica Cardiovascular Consultants in Oak Lawn, Ill. She works with an active cardiology practice and is a frequent lecturer on the management of heart failure
| | - Diana Sorbellini
- Diana Sorbellini is a staff nurse on the telemetry unit at Advocate Christ Medical Center in Oak Lawn. She specializes in the care of patients who have ventricular assist devices and was instrumental in developing the program described in this article
| | - Pamela Cianci
- Pamela Cianci is a heart failure clinical nurse specialist at Advocate Christ Medical Center. She has more than 20 years of experience in the management of patients with heart failure
| |
Collapse
|
27
|
Malani PN, Dyke DBS, Pagani FD, Chenoweth CE. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis 2002; 34:1295-300. [PMID: 11981723 DOI: 10.1086/340052] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2001] [Revised: 12/27/2001] [Indexed: 11/04/2022] Open
Abstract
Infection remains a serious complication of left ventricular assist device (LVAD) implantation. We performed a cohort study to assess infections among patients who underwent LVAD implantation from October 1996 through May 1999. Thirty-six LVADs were implanted in 35 patients; the mean duration (+/- standard deviation) of LVAD use was 73+/-60 days (total for all patients, 2565 days). Sixteen patients developed surgical site infections (SSIs; rate, 6.2 infections per 1000 LVAD days); 9 were deep-tissue or organ/space infections and 7 were superficial. Other infections included 7 cases of pneumonia (rate, 2.7 cases per 1000 LVAD days), 6 venous infections (rate, 2.3 per 1000 LVAD days), 2 bloodstream infections (rate, cases 0.8 per 1000 LVAD days), 3 urinary tract infections, and 2 skin and soft-tissue infections. Deep SSIs were associated with the requirement for postoperative hemodialysis (P=.02). Overall use of antibiotics was extensive, and a trend toward infection with antibiotic-resistant organisms was noted. Infections were a frequent complication of LVAD implantation. Further studies of interventions for preventing infection in LVAD recipients are warranted.
Collapse
Affiliation(s)
- Preeti N Malani
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, MI, 48109, USA.
| | | | | | | |
Collapse
|
28
|
Holman WL, Davies JE, Rayburn BK, McGiffin DC, Foley BA, Benza RL, Bourge RC, Blood P, Kirklin JK. Treatment of end-stage heart disease with outpatient ventricular assist devices. Ann Thorac Surg 2002; 73:1489-93; discussion 1493-4. [PMID: 12022538 DOI: 10.1016/s0003-4975(02)03502-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Initiating outpatient therapy with ventricular assist devices (VAD) was important in the progress of mechanical circulatory support. This article reviews our experience with VAD therapy from the start of our outpatient program until the present. METHODS Medical records of patients who received a Thoratec para-corporeal VAD, HeartMate vented electrical VAD, or HeartMate pneumatic VAD between 12/1/97 and 9/1/01 were reviewed. Variables included age, type of devices, total duration of VAD support, discharge status, duration of outpatient support, outcome (transplanted, died on support, ongoing), in-hospital length of stay after transplantation, and complications during VAD support. RESULTS There were 53 device implants in 46 patients. The cumulative patient-days of VAD support was 7,468 (mean duration of support, 138 +/- 195 days; median, 95 days; range, 2 to 948 days). Twenty of the 46 patients were discharged with a VAD. The cumulative outpatient days was 3,600 (mean outpatient duration, 157 +/- 164 days; median, 83 days; maximum, 560 days). Of the 20 outpatients, 11 received cardiac transplantation, 5 died, and 4 are ongoing as of 9/1/01. Major complications that occurred in the outpatient setting included 5 deaths after hospital readmission (1 sepsis, 1 conduit tear, 3 neurologic events); 4 device infections (3 sepsis, 1 pouch infection); and 3 device malfunctions that required reoperation for pump replacement (1 HeartMate pneumatic and 2 HeartMate vented electrical). No deaths occurred in an outpatient setting. CONCLUSIONS Ventricular assist devices effectively support outpatients for months to years. The anticipated time for postoperative recovery and VAD training before discharge is approximately 14 to 21 days, although shorter times may be possible in the future. Establishing a successful outpatient VAD program is a crucial step toward VAD as definitive therapy for end-stage heart disease.
Collapse
Affiliation(s)
- William L Holman
- Department of Surgery, University of Alabama at Birmingham, 35294-0007, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
McCarthy PM. Implantable left ventricular assist device bridge-to-transplantation: natural selection, or is this the natural selection? J Am Coll Cardiol 2002; 39:1255-7. [PMID: 11955840 DOI: 10.1016/s0735-1097(02)01764-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
30
|
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435-43. [PMID: 11794191 DOI: 10.1056/nejmoa012175] [Citation(s) in RCA: 2872] [Impact Index Per Article: 124.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Implantable left ventricular assist devices have benefited patients with end-stage heart failure as a bridge to cardiac transplantation, but their long-term use for the purpose of enhancing survival and the quality of life has not been evaluated. METHODS We randomly assigned 129 patients with end-stage heart failure who were ineligible for cardiac transplantation to receive a left ventricular assist device (68 patients) or optimal medical management (61). All patients had symptoms of New York Heart Association class IV heart failure. RESULTS Kaplan-Meier survival analysis showed a reduction of 48 percent in the risk of death from any cause in the group that received left ventricular assist devices as compared with the medical-therapy group (relative risk, 0.52; 95 percent confidence interval, 0.34 to 0.78; P=0.001). The rates of survival at one year were 52 percent in the device group and 25 percent in the medical-therapy group (P=0.002), and the rates at two years were 23 percent and 8 percent (P=0.09), respectively. The frequency of serious adverse events in the device group was 2.35 (95 percent confidence interval, 1.86 to 2.95) times that in the medical-therapy group, with a predominance of infection, bleeding, and malfunction of the device. The quality of life was significantly improved at one year in the device group. CONCLUSIONS The use of a left ventricular assist device in patients with advanced heart failure resulted in a clinically meaningful survival benefit and an improved quality of life. A left ventricular assist device is an acceptable alternative therapy in selected patients who are not candidates for cardiac transplantation.
Collapse
Affiliation(s)
- E A Rose
- College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Dew MA, Kormos RL, Winowich S, Harris RC, Stanford EA, Carozza L, Griffith BP. Quality of life outcomes after heart transplantation in individuals bridged to transplant with ventricular assist devices. J Heart Lung Transplant 2001; 20:1199-212. [PMID: 11704480 DOI: 10.1016/s1053-2498(01)00333-3] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND Increasing numbers of individuals receive ventricular assist devices (VADs) as bridges to heart transplantation. Physical morbidity risks and benefits, and quality of life (QOL) during VAD support have been documented. Effects of pre-transplant VAD support on functional and QOL outcomes after transplantation have received no empirical attention. METHODS Sixty-three VAD patients who received heart transplants underwent QOL evaluations of physical functioning, emotional and cognitive well-being, and social functioning at 2, 7, and 12 months after transplant (response rate = 95%). Ninety patients who had not received VADs--matched to the VAD group on cardiac-related and sociodemographic characteristics--served as longitudinal controls. RESULTS Both VAD and non-VAD groups showed similar levels and similar, statistically significant (p < 0.05) improvement in physical functioning (sleep, body care, mobility, ambulation, overall functional status, number of somatic complaints) across the study period. Emotional well-being (elevated depressive, anxiety, and anger symptoms; post-traumatic stress disorder rate) was stable or improved in both groups, and VAD patients showed significantly lower anxiety rates. The VAD patients' post-transplant cognitive status was significantly poorer. The VAD patients were significantly less likely to return to employment; other social functioning measurers (daily concerns, interpersonal activities/involvement, role function) showed mixed effects. Cognitive impairment explained much of the association between VAD support and post-transplant employment. CONCLUSIONS Although post-transplant physical and emotional recovery is similar in VAD and non-VAD patients, VAD patients retain more cognitive impairment and show mixed changes in social functioning. Increased attention to strategies to maximize VAD patients' cognitive capacity is required to facilitate social reintegration.
Collapse
Affiliation(s)
- M A Dew
- Department of Psychiatry, University of Pittsburgh School of Medicine and Medical Center, Pittsburg, Pennsylvania 15213, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Holman WL, Ormaza S, Seemuth K, Boehmer JP, Richenbacher WE. How to run an outpatient VAD program: overview. ASAIO J 2001; 47:588-9. [PMID: 11730192 DOI: 10.1097/00002480-200111000-00003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- W L Holman
- Department of Surgery, University of Alabama at Birmingham, 35294-0007 USA
| | | | | | | | | |
Collapse
|
33
|
Holman WL. Mechanical circulatory support: expanding knowledge and experience in a challenging patient subset. Intensive Care Med 2001; 27:1245-6. [PMID: 11511934 DOI: 10.1007/s001340101030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/07/2001] [Indexed: 11/27/2022]
|
34
|
Grady KL, Meyer P, Mattea A, White-Williams C, Ormaza S, Kaan A, Todd B, Chillcott S, Dressler D, Fu A, Piccione W, Costanzo MR. Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation. J Heart Lung Transplant 2001; 20:657-69. [PMID: 11404172 DOI: 10.1016/s1053-2498(01)00253-4] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND The successful use of left ventricular assist devices (LVADs) as a bridge to heart transplantation has prompted our examination of quality of life (QOL) outcomes. The purposes of this study are to describe QOL in patients 1 to 2 weeks after LVAD implantation and to compare QOL in a smaller cohort of patients from before to 1 to 2 weeks after surgery. METHODS Data were collected from a convenience sample of 81 patients who completed booklets of questionnaires that measure domains of QOL 1 to 2 weeks after LVAD insertion and from 30 of 81 patients who completed booklets at both the pre-implantation and post-implantation periods. Patients completed booklets of 6 to 8 self-reporting instruments, with acceptable reliability and validity. Data were analyzed using descriptive and comparative statistics (chi-square, Mann-Whitney U and Wilcoxon signed ranks tests) with p = 0.01 considered statistically significant. RESULTS One to 2 weeks after LVAD implantation, patients were quite satisfied with their lives, experienced moderately low amounts of stress, coped well, and perceived themselves as having good health and QOL, low symptom distress, and moderately low functional disability. Patients reported significantly better QOL, more satisfaction with health and functioning, and were significantly less distressed by symptoms from immediately pre-operatively to post-operatively. However, patients reported significantly more self-care disability and more dissatisfaction with socioeconomic areas of life from before to immediately after surgery. Psychological distress was low and did not change with time. CONCLUSION Given that QOL improved from before to after LVAD implantation, our findings provide a springboard for investigation of the impact of LVADs on long-term QOL outcomes.
Collapse
Affiliation(s)
- K L Grady
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612-3824, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
As cardiac surgery centers appreciate that ventricular assist devices (VAD) can dramatically impact patient survival as a bridge to transplant or recovery, and possibly permanent therapy, increasing numbers will desire to establish mechanical support programs. A number of vital elements must be put in place in order to operate a successful mechanical support program. Of utmost importance is the assembly of a dedicated team focused on comprehensive care of critically ill patients in need of circulatory support. An ongoing commitment from anesthesiologists, cardiologists, nephrologists, and other support staff is essential. Selection of complementary assist devices should be made to cover the spectrum of required support scenarios, both short- and long-term. Outpatient therapy has become increasingly important in mechanical cardiac assistance and establishment of an office where "LVAD coordinators" see outpatients facilitates this aspect of the program. Critically ill patients in need of cardiac assistance may benefit from specialized medical therapies such as: (1) intravenous arginine vasopressin for vasodilatory hypotension; (2) inhaled nitric oxide for right heart failure; (3) aprotinin to reduce hemorrhage; and (4) early enteral feeding in an effort to reduce infectious complications and improve rehabilitation following VAD implantation. A regional network with spoke hospitals centered around a hub hospital with long-term VAD and heart transplant programs can improve survival of patients with postcardiotomy cardiogenic shock via early transfer to the hub hospital. In this article, we describe the components of our mechanical support program that have allowed us to successfully support patients with heart failure in need of circulatory support.
Collapse
Affiliation(s)
- D N Helman
- Division of Cardiothoracic Surgery, Columbia-Presbyterian Medical Center, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
| | | |
Collapse
|
36
|
Zytowski M, Baumann G, Hotz H, Dushe S, Enzweiler C, Borges A, Borak V, Redmann K, Lunkenheimer PP, Konertz W. Results of Batista Procedure in Ischemic Dilated Cardiomyopathy. Asian Cardiovasc Thorac Ann 2000. [DOI: 10.1177/021849230000800402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
From March 1995 to April 1998, 24 men and 5 women (mean age, 62.2 ± 10 years) underwent the Batista procedure for end-stage cardiac dysfunction due to ischemic dilated cardiomyopathy. Preoperatively, mean cardiac index was 1.9 ± 0.3 L·min−1·m−2, stroke index was 25 ± 5 mL·beat−1·m−2, ejection fraction was 20% ± 6%, and 22 (79%) patients were in New York Heart Association functional class IV. Associated procedures were coronary bypass (25), mitral valvuloplasty (15), aortic or mitral valve replacement (5), dynamic cardiomyoplasty (2), and aneurysmectomy (1). One patient (3.4%) died early and 3 (10.3%) died later. The 1- and 2-year actuarial survival was 87%. A left ventricular assist device was required in 2 patients during the follow-up period. Postoperatively, cardiac index was 2.9 ± 0.3 L·min−1·m−2, stroke index was 36 ± 5 mL·beat−1·m−2, and ejection fraction was 38% ± 10%. Left ventricular end-diastolic diameter decreased from 71 ± 8 mm to 55 ± 8 mm. Currently, 88% of survivors are in functional class I or II. It was concluded that the Batista procedure significantly improved objective and subjective parameters of cardiac performance during early and intermediate follow-up.
Collapse
Affiliation(s)
| | - Gert Baumann
- Department of Cardiology, Angiology, and Pulmonology, Charité Humboldt University Berlin, Berlin, Germany
| | | | | | - Christian Enzweiler
- Department of Radiology, Charité Humboldt University Berlin, Berlin, Germany
| | - Adrian Borges
- Department of Cardiology, Angiology, and Pulmonology, Charité Humboldt University Berlin, Berlin, Germany
| | - Viola Borak
- Department of Anesthesiology, Charité Humboldt University Berlin, Berlin, Germany
| | - Klaus Redmann
- Department of Thoracic and Cardiovascular Surgery, University of Münster Münster, Germany
| | | | | |
Collapse
|
37
|
Peterzén B, Granfeldt H, Lönn U, Carnstam B, Nylander E, Dahlström U, Rutberg H, Casimir-Ahn H. Management of patients with end-stage heart disease treated with an implantable left ventricular assist device in a nontransplanting center. J Cardiothorac Vasc Anesth 2000; 14:438-43. [PMID: 10972612 DOI: 10.1053/jcan.2000.7943] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To describe the setup of a left ventricular assist device (LVAD) program in a nontransplanting center. DESIGN A prospective study from February 1993 to June 1999. SETTING A university hospital. PARTICIPANTS Ten patients, 6 men, with a mean age of 44 years (range 16 to 63 years) and with end-stage heart failure resulting from dilated cardiomyopathy (n = 7) or ischemic heart disease (n = 3). INTERVENTIONS The patients received the TCI (Thermo Cardiosystems Inc, Woburn, MA) Heart Mate implantable assist device. Five patients had a pneumatic device, and 5 had an electric device. All except 1 patient with an electric device had the pump for an extended period. MEASUREMENTS AND MAIN RESULTS Median time on the ventilator was 6.2 days, and median time in the ICU was 14 days. Significant hemodynamic improvement was observed by echocardiography and invasive monitoring. Milrinone and epinephrine supplemented by prostaglandin E1 were the most commonly used drugs to avoid right-sided heart failure. Nine patients were transplanted after pump therapy of 241 days (median) (range, 56 to 873 days). One patient died because of endovascular infection and septicemia. Infectious complications were frequent, especially when the pump time was extended. CONCLUSIONS The introduction of an LVAD program in a nontransplanting center can be achieved with good results. Intense collaboration with a transplant center is mandatory. The complication rate increased when treatment times were extended.
Collapse
Affiliation(s)
- B Peterzén
- Linköping Heart Center, University Hospital, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Morales DL, Argenziano M, Oz MC. Outpatient left ventricular assist device support: a safe and economical therapeutic option for heart failure. Prog Cardiovasc Dis 2000; 43:55-66. [PMID: 10935558 DOI: 10.1053/pcad.2000.7199] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The left ventricular assist device (LVAD), once considered for acute cardiac failure only when no other therapeutic option was available, is now used routinely at selected centers to allow the sickest patients to become self-sufficient and go home. This represents a dramatic change in the physician's perception of the LVAD in the early 1990s. The creation of these mechanical assist outpatient programs are possible for the following reasons: 1) confidence in the devices allow patients, their families, and health care providers to be more comfortable with outpatient therapy; 2) the devices are simplified and durable, allowing extended duration of support and more options for patients; and 3) a change in the perception of the LVAD from a last-resort therapeutic option to that of a safe and reliable bridge to recovery and transplant. With these general concepts in mind, programs have been created with specific safety nets, patient education goals, and discharge criteria. By using this construct, we have developed a successful outpatient LVAD program in which 70% of our vented electric LVAD patients were discharged with a 0% mortality and minimal morbidity. From our experience and studies, we believe that not only is an outpatient LVAD program safe and economical, but it is also socially, physically, and psychologically beneficial to the patient. In the current economic environment of cost containment, outpatient LVAD therapy is a necessary part of an LVAD program that should be sought by most cardiac mechanical assist programs.
Collapse
Affiliation(s)
- D L Morales
- Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY, USA.
| | | | | |
Collapse
|
39
|
Abstract
End-stage heart failure exerts a tremendous impact on individuals and society in terms of personal and economic suffering. The development of mechanical circulatory support devices has been driven by the shortage of donor organs for heart transplantation. Collaborative efforts in the fields of surgery, medicine, and biomedical engineering, sponsored by both government and industry, have led to devices capable of providing reliable circulatory support. Future mechanical cardiac assist devices will likely play an important role in the treatment of an ever-growing population of patients with end-stage heart failure.
Collapse
Affiliation(s)
- D N Helman
- Department of Surgery, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center, New York, NY, USA
| | | |
Collapse
|
40
|
Kasirajan V, McCarthy PM, Hoercher KJ, Starling RC, Young JB, Banbury MK, Smedira NG. Clinical experience with long-term use of implantable left ventricular assist devices: indications, implantation, and outcomes. Semin Thorac Cardiovasc Surg 2000; 12:229-37. [PMID: 11052190 DOI: 10.1053/stcs.2000.9667] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We describe our clinical experience with 205 implantable left ventricular assist devices at the Cleveland Clinic between December 1991 and January 2000, along with manufacturers' data submitted to the Food and Drug Administration. In patients with end-stage cardiac failure who are suitable candidates for transplantation, these devices serve as excellent bridges to transplantation. Recent modifications have increased pump reliability and reduced thromboembolic rates. The vented electric HeartMate (Thermocardiosystems Inc, Woburn, MA) and the Novacor (Baxter-Novacor, Oakland, CA) left ventricular assist systems allow patients to be discharged from the hospital while awaiting a donor heart. Experience with long-term support is providing insights into permanent implantation of these devices as destination therapy. Although infection remains a major impediment to long-term support, patient-pump interactions leading to changes in the coagulation and immune systems are being recognized, and these interactions may have important implications with respect to thromboembolism, infection, and sensitization to human leukocyte antigens (HLAs). Better understanding of these factors may eventually lead to the development of permanently implantable pumps as an alternative to transplantation.
Collapse
Affiliation(s)
- V Kasirajan
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, OH, USA
| | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
There are now 3 commercially approved intracorporeal left ventricular assist devices (LVADs). Product similarities include (1) LV apex, to pump, to ascending aorta flow patterns, (2) excellent hemodynamic support with reversal of heart failure and neurohormone/cytokine milieu, and (3) the requirement of major surgery for device implantation and later explantation, with or without transplant. Two electrically powered models allow a tether-free existence and hospital discharge. All complications are being addressed, and in the past decade, device failure and thromboemboli have been reduced. Infection continues to be an obstacle to more widespread adoption of therapy. Despite pre-LVAD shock, most patients (65% to 78% by Food and Drug Administration data) survive until transplant (averaging 80 to 96 days of LVAD support), and posttransplant survival is equal to nonbridged patients. As the problem of infection is reduced, more widespread LVAD use can be anticipated.
Collapse
Affiliation(s)
- P M McCarthy
- Kaufman Center for Heart Failure, Department of Thoracic & Cardiovascular Surgery, The Cleveland Clinic Foundation, OH, USA.
| | | |
Collapse
|
42
|
Bank AJ, Mir SH, Nguyen DQ, Bolman RM, Shumway SJ, Miller LW, Kaiser DR, Ormaza SM, Park SJ. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Ann Thorac Surg 2000; 69:1369-74; discussion 1375. [PMID: 10881807 DOI: 10.1016/s0003-4975(00)01083-3] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND Left ventricular assist devices (LVADs) are increasingly being used to "bridge" patients to heart transplantation. METHODS Data from 40 consecutive status 1 heart transplantation patients treated with intravenous inotrope therapy (n = 20) or the HeartMate LVAD (n = 20) were retrospectively analyzed. RESULTS Baseline clinical characteristics were similar in the two groups. At the time of transplantation, LVAD patients had significantly higher blood pressure and sodium with significantly lower blood urea nitrogen and creatinine. After transplantation, renal failure (52.6% versus 16.7%) and right heart failure (31.6% versus 5.6%) occurred more frequently (p < 0.05) in the inotrope group. Six-month survival after transplantation did not significantly differ in the inotrope or LVAD groups (73.7% versus 88.9%) but event-free survival was significantly (p < 0.05) lower in the inotrope group (15.8% versus 55.6%). Total hospital charges were significantly lower in the inotrope group ($213,860 +/- $107,560 versus $342,620 +/- $104,420), but average daily hospital charges were not different ($3,990 +/- $1,300 versus $4,130 +/- $2,050). CONCLUSIONS Status 1 heart transplant patients treated with an LVAD as opposed to inotrope therapy have improved clinical and metabolic function at the time of transplant and improved survival to 6 months after transplant without major complications. Total costs are higher in the LVAD patients but average daily costs are similar.
Collapse
Affiliation(s)
- A J Bank
- Department of Medicine, University of Minnesota, Minneapolis, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Morales DL, Catanese KA, Helman DN, Williams MR, Weinberg A, Goldstein DJ, Rose EA, Oz MC. Six-year experience of caring for forty-four patients with a left ventricular assist device at home: safe, economical, necessary. J Thorac Cardiovasc Surg 2000; 119:251-9. [PMID: 10649200 DOI: 10.1016/s0022-5223(00)70180-2] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE With increasing numbers of implantations, left ventricular assist device programs can put a financial strain on a hospital unless an efficient and safe outpatient program is developed. However, the left ventricular assist device is not widely recognized in the medical community as being reliable enough to support a patient at home. We reviewed our experience with these patients at home to assess the safety and the benefits of such a program. METHODS Our institutional 6-year experience with 90 consecutive recipients of a wearable left ventricular assist device was analyzed. RESULTS Forty-four (49%) of the 90 patients who received TCI vented-electric left ventricular assist devices (Thermo Cardiosystems, Inc, Woburn, Mass) were discharged, spending a total of 4546 days (12.5 years) at home with an average of 103 +/- 16 days of outpatient support (range 9-436 days). Of these 44 patients, all were successfully bridged to transplantation (42 patients, 96%) or planned explantation (2 patients, 4%). None of the outpatients died. The cumulative events per outpatient month were 0.020 for bleeding, 0.053 for device infection, 0.0068 for thromboembolus, and 0.020 for major malfunctions. Our estimated average cost to bridge a patient to transplantation or explantation once discharged is $13,200 and as an inpatient over the same length of time, including only room and board, is $165,200. Thirty percent of outpatients were able to return to work or school, 33% to sexual activity, and 44% to driving. All outpatients performed activities of daily living. CONCLUSION Current left ventricular assist device technology provides effective and economical outpatient support and is associated with limited morbidity and a satisfactory quality of life.
Collapse
Affiliation(s)
- D L Morales
- Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY, USA.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Tagusari O, Kormos RL, Kawai A, Yamazaki K, Pham SM, Hattler BG, Murali S, Griffith BP. Native heart complications after heterotopic heart transplantation: insight into the potential risk of left ventricular assist device. J Heart Lung Transplant 1999; 18:1111-9. [PMID: 10598735 DOI: 10.1016/s1053-2498(99)00080-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND In heterotopic heart transplantation, the donor heart is connected parallel to the recipient's diseased heart. Recipients continue to have risks, such as arrhythmia, thromboembolism, valvular heart disease, and ischemic heart disease which can develop in the native heart. It may serve as a clinical model to study long-term pathophysiologic processes in the native heart of patients with a left ventricular assist device. METHOD We analyzed the prevalence of long-term complications related to the native heart in the heterotopic heart transplant and attempted to gain insight into the potential risk to a native heart after receiving a left ventricular assist device. RESULTS Between December 1984 and December 1994, 16 patients (13 men, 3 women, ranging in age from 37 to 60 years) underwent heterotopic heart transplant at the University of Pittsburgh. The 1- and 5-year survival rate after the transplant was 81% and 44%, respectively. Actuarial freedom from complications related to the native heart after 1 year and 4 years was ventricular arrhythmia: 85%, 75%; ischemic disease: 85%, 64%; valvular disease: 100%, 88%; and thromboembolism: 85%, 58%. Of these complications, thromboembolism was not considered in determining actuarial freedom from complications because thromboembolism should be regarded as a device-related complication rather than as a native-heart-related complication for left ventricular assist device recipients. Consequently, actuarial freedom from all complications excluding thromboembolism was 70% after 1 year and 50% after 4 years. In addition, the hazard function curve remains constant up to 80 months after the operation without significant differences among the yearly ratios. CONCLUSIONS This analysis suggests that cautious observation of the native heart's long-term performance is necessary for the left ventricular assist device recipient.
Collapse
Affiliation(s)
- O Tagusari
- Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania, USA.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Choi L, Choudhri AF, Pillarisetty VG, Sampath LA, Caraos L, Brunnert SR, Oz MC, Modak SM. Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections. J Heart Lung Transplant 1999; 18:1103-10. [PMID: 10598734 DOI: 10.1016/s1053-2498(99)00076-5] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND Infection remains the single most important challenge to extended left ventricular assist device (LVAD) use and often arises from the percutaneous driveline exit site. We evaluated the ability of an LVAD driveline prototype impregnated with chlorhexidine, triclosan, and silver sulfadiazine to resist bacterial and fungal colonization. METHODS The spectrum and duration of antimicrobial activity were evaluated in vitro by daily transfer of driveline segments embedded on agar plates inoculated with 10(8) colony-forming units (CFU) of Staphylococcus aureus (S. aureus), Staphlococcus epidermidis, Enterobacter aerogenes, Psuedomonas aeruginosa, and Candida albicans, and then measuring zones of inhibition around the sample subsequent to 24 hours of incubation at 37 degrees C. Antimicrobial activity was demonstrated against all organisms for greater than 14 days, and for over 21 days for gram-positive bacteria. To demonstrate in vivo efficacy of the treated driveline, 3-cm segments of driveline were implanted in the dorsal and ventral surface of rats. The exit site was inoculated with 10(6) CFU of S. aureus. After 7 days, driveline segments were aseptically explanted and assayed for bacterial colonization and retention of antimicrobial activity. One hundred percent of control segments were colonized (10(5) CFU S. aureus/cm) as against 13% of the test explants (< or = 330 CFU/cm; p < 0.0001). RESULTS Subcultures of the insertion site and driveline pocket tissue resulted in 10(3) to 10(5) CFU per swab culture for control rats and 0 to 10(2) CFU/swab for test animals. Test drivelines retained 80% of anti-S. aureus activity. Gross and histological examination of the driveline and surrounding pocket revealed minimal tissue reactivity with positive signs of tissue ingrowth. CONCLUSION An antimicrobial driveline may prevent early infections and facilitate ingrowth of tissue to provide long-term stability and protection against late infection.
Collapse
Affiliation(s)
- L Choi
- Department of Surgery, Columbia University, New York, New York, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Helman DN, Morales DL, Edwards NM, Mancini DM, Chen JM, Rose EA, Oz MC. Left ventricular assist device bridge-to-transplant network improves survival after failed cardiotomy. Ann Thorac Surg 1999; 68:1187-94. [PMID: 10543478 DOI: 10.1016/s0003-4975(99)00911-x] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Postcardiotomy cardiogenic shock has been reported to occur following 2% to 6% of cardiac surgical procedures. Both the mandatory New York state cardiac surgery database and a voluntary ventricular assist device registry have reported hospital discharge rates of only 25% in postcardiotomy patients supported with ventricular assist devices. Although many centers have access to short-term mechanical cardiac assist devices, most lack a dedicated team which can resuscitate these critically ill patients. Equally important, these centers do not have easy access to effective cardiac replacement options, including implantable left ventricular assist devices (LVADs) and heart transplantation. METHODS A referral network based upon the use of implantable LVADs as a bridge to transplantation in patients with postcardiotomy heart failure was established in the New York City region. Cardiac surgery centers were encouraged to contact our center early following any failed cardiotomy. RESULTS Forty-four patients entered our postcardiotomy network: 12 recovered without an implantable LVAD, 23 received implantable LVADs, and six expired without long-term LVAD support. Of the 44 referrals, 29 (66%) survived to hospital discharge. Of the 23 patients receiving implantable LVADs, two recovered myocardial function and underwent LVAD explant, 14 were bridged to heart transplant, one underwent an emergent heart transplant, and six expired. Of the 23 implantable LVAD patients, 17 (74%) survived to hospital discharge. CONCLUSIONS Regional networks centered around bridge-to-transplant facilities that have an aggressive approach to implantable LVAD placement may substantially improve the survival rate of patients with postcardiotomy heart failure.
Collapse
Affiliation(s)
- D N Helman
- Division of Cardiothoracic Surgery, Columbia-Presbyterian Medical Center, New York, New York 10032, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Petrucci R, Kushon D, Inkles R, Fitzpatrick J, Twomey C, Samuels L. Cardiac ventricular support. Considerations for psychiatry. PSYCHOSOMATICS 1999; 40:298-303. [PMID: 10402874 DOI: 10.1016/s0033-3182(99)71222-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Cardiac ventricular support is fostering additional roles for psychiatric consultation with this vulnerable end-of-life cardiac group. Incidence of premorbid and postsurgical psychiatric disorders (Axis I), psychotropic use, neurologic events, and mortality was obtained for 21 Novacor left-ventricular assist system patients prospectively and 13 Abiomed left/right ventricular-assist device patients retrospectively. This fragile patient population and their families warrant involvement for psychiatry because of the extreme conditions and consequences associated with mechanical cardiac assistance. The authors address psychiatric morbidity and neurobehavioral modifications associated with ventricular support.
Collapse
Affiliation(s)
- R Petrucci
- MCP Hahnemann University, Heart Failure/Transplant Center, Philadelphia Pennsylvania 19102, USA
| | | | | | | | | | | |
Collapse
|
48
|
Abstract
BACKGROUND During the last four decades substantial efforts have been made in the development of effective mechanical circulatory devices. Since the first clinical utilization in the 1960s, the field has gone from the stage of clinical experimentation to that of a valid and effective heart failure treatment alternative. Experience gained during the short-term use of these devices, typically as a bridge to cardiac transplantation, has led to increased expectations of devices capable of long-term or permanent support to be used as a permanent treatment for end-stage heart failure patients. This article reviews the history, current state of the art, and future of the field of mechanical circulatory devices. METHODS Mechanical circulatory devices can be classified into three major categories: (1) total artificial hearts, (2) pulsatile ventricular assist devices, and (3) nonpulsatile ventricular assist devices. The most widely used devices have been the pulsatile ventricular assist devices with more than 5,800 reported cases, whereas the use of total artificial hearts has been limited to less than 350 reported cases. Nonpulsatile devices have been used clinically, but only in short-term cases (i.e., hours and days), whereas the pulsatile devices have been used in the long-term application, with patients supported for weeks, months, and in a small number of cases, years. The technological evolution of these devices has gone from large, extracorporeal systems designed to keep the patient alive in the intensive care unit (ICU) until a donor organ could be found, to portable devices that allow the patient to be mobilized outside of the hospital setting. RESULTS The clinical experience with mechanical circulatory devices as a bridge to cardiac transplantation has saved the lives of thousands of patients. Exciting new research discoveries related to recovery of native heart function during extended circulatory support have provided new hope for many more patients. Additional research efforts currently underway are being tested at various laboratories around the world and will soon provide the next generation of systems. These new systems will offer the recipients an unparalleled quality of life with minimal limitations on daily activities. The progress in this field has reached the point where circulatory support will soon be considered a valid long-term or permanent therapy and an elective to transplantation.
Collapse
Affiliation(s)
- T Mussivand
- The Cardiovascular Devices Division, University of Ottawa Heart Institute, Ontario, Canada
| |
Collapse
|
49
|
Thomas NJ, Harvey AT. Bridge to recovery with the Abiomed BVS-5000 device in a patient with intractable ventricular tachycardia. J Thorac Cardiovasc Surg 1999; 117:831-2. [PMID: 10096985 DOI: 10.1016/s0022-5223(99)70310-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- N J Thomas
- Cardiovascular Research/Care Foundation, Phoenix, AZ, USA.
| | | |
Collapse
|
50
|
Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Stevenson LW, Shapiro PA, Lazar RM, Watson JT, Goldstein DJ, Gelijns AC. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg 1999; 67:723-30. [PMID: 10215217 DOI: 10.1016/s0003-4975(99)00042-9] [Citation(s) in RCA: 284] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND Because left ventricular assist devices have recently been approved by the Food and Drug Administration to support the circulation of patients with end-stage heart failure awaiting cardiac transplantation, these devices are increasingly being considered as a potential alternative to biologic cardiac replacement. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial is a multicenter study supported by the National Heart, Lung, and Blood Institute to compare long-term implantation of left ventricular assist devices with optimal medical management for patients with end-stage heart failure who require, but do not qualify to receive cardiac transplantation. METHODS We discuss the rationale for conducting REMATCH, the obstacles to designing this and other randomized surgical trials, the lessons learned in conducting the multicenter pilot study, and the features of the REMATCH study design (objectives, target population, treatments, end points, analysis, and trial organization). CONCLUSIONS We consider what will be learned from REMATCH, expectations for expanding the use of left ventricular assist devices, and future directions for assessing clinical procedures.
Collapse
Affiliation(s)
- E A Rose
- International Center for Health Outcomes and Innovation Research, Columbia University, New York, New York 10032, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|